Instrument Inactif

Autres langues Abpro Corporation Nasdaq

Actions

US0008501076

Recherche biotechnologique et médicale

Autres langues

20/05	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/04	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
15/04	Abpro Holdings, Inc. Auditor Raises 'Going Concern' Doubt
25/02	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index
20/02	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index
03/02	Abpro Holdings, Inc. Announces Board and Committee Resignations
23/01	Abpro Holdings, Inc. Announces Board and Committee Changes
17/01	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding
15/01	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
06/01	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance
06/01	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
06/01	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
15/12	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers
15/12	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
15/12	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers
09/12	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
14/11	Abpro Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
07/11	Abpro Holdings files prospectus related to the offer and resale of up to 9.78 million shares of common stock - SEC filing
04/11	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
03/11	Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
22/10/25	Abpro Holdings Inc - to effect one-for-thirty reverse stock split - SEC filing
02/10/25	Abpro Holdings, Inc. Announces Termination of Robert J. Markelewicz as Chief Medical Officer, Effective November 30, 2025
13/08/25	Abpro Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
15/05/25	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
27/04/25	Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager